Intellectual disability (ID) and autism spectrum disorder (ASD) are common, co-occurring developmental disorders and are frequently associated with sleep problems. This study aimed to assess the effectiveness and tolerability of agomelatine as a pharmacotherapy for sleep problems in ASD adults with ID.
Method:
A randomised, crossover, triple-blind, placebo-controlled clinical trial, with two three-month periods of treatment starting with either agomelatine or placebo and a washout period of two weeks. Ambulatory circadian monitoring (24 hours/7 days) evaluated total sleep time (TST) as the primary outcome variable.
Results:
Participants (N=23; 35±12 years old; 83% male) had a median of three (interquartile range (IQR) 1–4) co-morbidities and were taking a median of five (IQR 2–7) prescribed drugs. Before agomelatine or placebo treatment, all subjects presented with insomnia symptoms, including sleep latency (100% abnormal, 55±23 minutes) or TST (55% abnormal, 449±177 minutes), and 66% had circadian rhythm sleep–wake abnormalities with rhythm phase advancements according to the M5 sleep phase marker values. During the three-month agomelatine treatment, night TST significantly increased by a mean of 83 minutes (16% abnormal, 532±121 minutes), together with a phase correction (M5 1:45±2:28 hours vs. 3:15±2:20 hours), improving sleep stability in wrist temperature rhythm (0.43±0.29 vs. 0.52±0.18 AU). Adverse events were mild and transient.
Conclusions:
Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.
AllikHLarssonJ-OSmedjeH (2008) Sleep patterns in school-age children with Asperger syndrome or high-functioning autism: a follow-up study. J Autism Dev Disord38: 1625–1633.
2.
AndersenIMKaczmarskaJMcGrewSG, et al. (2008) Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol23: 482–485.
3.
AronenETPaavonenEJFjällbergM, et al. (2000) Sleep and psychiatric symptoms in school-age children. J Am Acad Child Adolesc Psychiatry39: 502–508.
4.
AugerRRBurgessHJEmensJS, et al. (2015) Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep–wake disorders: advanced sleep–wake phase disorder (ASWPD), delayed sleep–wake phase disorder (DSWPD), non-24-hour sleep–wake rhythm disorder (N24SWD), and irregular sleep–wake rhythm disorder (ISWRD). An update for 2015. J Clin Sleep Med11: 1199–1236.
5.
BakerEKRichdaleAL (2015) Sleep patterns in adults with a diagnosis of high-functioning autism spectrum disorder. Sleep38: 1765–1774.
6.
BakerEKRichdaleAL (2017) Examining the behavioural sleep–wake rhythm in adults with autism spectrum disorder and no comorbid intellectual disability. J Autism Dev Disord47: 1207–1222.
7.
BakerEKRichdaleALHaziA, et al. (2017) Assessing the dim light melatonin onset in adults with autism spectrum disorder and no comorbid intellectual disability. J Autism Dev Disord47: 2120–2137.
8.
Bonmati-CarrionMMiddletonBRevellV, et al. (2014) Circadian phase asessment by ambulatory monitoring in humans: correlation with dim light melatonin onset. Chronobiol Int31: 37–51.
9.
BuckleyAWSassowerKRodriguezAJ, et al. (2011) An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol21: 353–357.
10.
CalabreseJRGuelfiJDPerdrizet-ChevallierC (2007) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord9: 628–635.
11.
CalandreESlimMGarcia-LeivaJ, et al. (2014) Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study. Pharmacopsychiatry47: 67–72.
12.
CarskadonMADementWC (2005) Normal human sleep: an overview. Prin Prac Sleep Med4: 13–23.
13.
CohenSFulcherBDRajaratnamSM, et al. (2018) Sleep patterns predictive of daytime challenging behavior in individuals with low-functioning autism. Autism Res11: 391–403.
14.
CortesiFGiannottiFSebastianiT, et al. (2012) Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res21: 700–709.
15.
CroenLAZerboOQianY, et al. (2015) The health status of adults on the autism spectrum. Autism19: 814–823.
16.
CrowleyK (2011) Sleep and sleep disorders in older adults. Neuropsychol Rev21: 41–53.
17.
de Faria PoloniJFeltesBCBonattoD (2011) Melatonin as a central molecule connecting neural development and calcium signaling. Funct Integr Genomics11: 383–388.
18.
DevnaniPAHegdeAU (2015) Autism and sleep disorders. J Pediatr Neurosci10: 304.
19.
EllisCLemmensGParkesJ (1996) Melatonin and insomnia. J Sleep Res5: 61–65.
20.
EnglischSJungHSLewienA, et al. (2016) Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: an open-prospective proof-of-concept study. J Clin Psychopharmacol36: 597–607.
21.
FadiniCCLamônicaDAFett-ConteAC, et al. (2015) Influence of sleep disorders on the behavior of individuals with autism spectrum disorder. Front Hum Neurosci9: 347.
22.
GarstangJWallisM (2006) Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev32: 585–589.
23.
GeoffrayMMNicolasASperanzaM, et al. (2016) Are circadian rhythms new pathways to understand autism spectrum disorder?J Physiol Paris110: 434–438.
24.
GoldmanSEAdkinsKWCalcuttMW, et al. (2014) Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord44: 2525–2535.
25.
GringrasPNirTBreddyJ, et al. (2017) Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry56: 948–957.e944.
26.
GvozdjákováAKucharskáJOstatníkováD, et al. (2014) Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev2014: 6p.
27.
HaleACorralR-MMencacciC, et al. (2010) Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol25: 305–314.
28.
HareDJJonesSEvershedK (2006a) A comparative study of circadian rhythm functioning and sleep in people with Asperger syndrome. Autism10: 565–575.
29.
HareDJJonesSEvershedK (2006b) Objective investigation of the sleep–wake cycle in adults with intellectual disabilities and autistic spectrum disorders. J Intellect Disabil Res50: 701–710.
30.
IshizakiASugamaMTakeuchiN (1999) [Usefulness of melatonin for developmental sleep and emotional/behavior disorders – studies of melatonin trial on 50 patients with developmental disorders]. No To Hattatsu31: 428–437.
31.
JanJEO’DonnellME (1996) Use of melatonin in the treatment of paediatric sleep disorders: mini review. J Pineal Res21: 193–199.
32.
JohnsonKPMalowBA (2008) Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am17: 773–785.
33.
JonesKBCottleKBakianA, et al. (2016) A description of medical conditions in adults with autism spectrum disorder: a follow-up of the 1980s Utah/UCLA Autism Epidemiologic Study. Autism20: 551–561.
34.
KentJMHoughDSinghJ, et al. (2013) An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol23: 676–686.
35.
KrauchiKCajochenCMoriD, et al. (1997) Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol Regul Integr Comp Physiol272: R1178–R1188.
36.
LauxGGroupVS (2012) The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry45: 284–291.
37.
LemoinePGuilleminaultCAlvarezE (2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry68: 1723–1732.
38.
LeproultRVan OnderbergenAL’Hermite-BalériauxM, et al. (2005) Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol63: 298–304.
39.
MalowBAAdkinsKWMcGrewSG, et al. (2012) Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord42: 1729–1737.
40.
MalowBAMacDonaldLLFawkesDB, et al. (2016) Teaching children with autism spectrum disorder how to sleep better: a pilot educational program for parents. Clin Pract Pediatr Psychol4: 125.
41.
MarasASchroderCMMalowBA, et al. (2018) Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol28: 699–710.
42.
Martinez-NicolasAOrtiz-TudelaEMadridJA, et al. (2011) Crosstalk between environmental light and internal time in humans. Chronobiol Int28: 617–629.
43.
MatsonJLAnconaMNWilkinsJ (2008) Sleep disturbances in adults with autism spectrum disorders and severe intellectual impairments. J Intellect Disabil Offending Behav1: 129–139.
44.
McArthurAJBuddenSS (1998) Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol40: 186–192.
45.
McHillAWWrightKPJr (2017) Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease. Obes Rev18: 15–24.
46.
MelkeJBotrosHGChasteP, et al. (2008) Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry13: 90–98.
47.
MundeyKBenloucifSHarsanyiK, et al. (2005) Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep28: 1271–1278.
48.
NewcombETHagopianLP (2018) Treatment of severe problem behaviour in children with autism spectrum disorder and intellectual disabilities. Int Rev Psychiatry30: 96–109.
49.
Ortiz-TudelaEMartinez-NicolasACamposM, et al. (2010) A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol6: e1000996.
50.
Ortiz-TudelaEMartinez-NicolasADíaz-MardomingoC, et al. (2014) The characterization of biological rhythms in mild cognitive impairment. Biomed Res Int2014: 524971.
51.
ØyaneNMBjorvatnB (2005) Sleep disturbances in adolescents and young adults with autism and Asperger syndrome. Autism9: 83–94.
52.
PaavonenEJNieminen-von WendtTVanhalaR, et al. (2003) Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol13: 83–95.
53.
PjrekEWinklerDKonstantinidisA, et al. (2007) Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology190: 575–579.
54.
PoluéktovMLevinYI (2013) The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study). Zh Nevrol Psikhiatr113: 39–44.
55.
PribytkovAPanovaNPopovaYV, et al. (2013) Efficacy of agomelatine in depressive disorders with anxiety. Zh Nevrol Psikhiatr113: 53–58.
56.
Quera-SalvaM-AHajakGPhilipP, et al. (2011) Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol26: 252–262.
57.
RichdaleALSchreckKA (2009) Sleep problems in autism spectrum disorders: prevalence, nature, and possible biopsychosocial aetiologies. Sleep Med Rev13: 403–411.
58.
RossignolDAFryeRE (2011) Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol53: 783–792.
59.
SalvaM-AQVanierBLaredoJ, et al. (2007) Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychoph10: 691–696.
60.
SaperCBScammellTELuJ (2005) Hypothalamic regulation of sleep and circadian rhythms. Nature437: 1257.
61.
SarabiaJRolMMendiolaP, et al. (2008) Circadian rhythm of wrist temperature in normal-living subjects: a candidate of new index of the circadian system. Physiol Behav95: 570–580.
62.
SateiaMJ (2014) International classification of sleep disorders. Chest146: 1387–1394.
63.
ScahillLJeonSBoorinSJ, et al. (2016) Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry55: 415–423.
64.
SciglianoGRonchettiG (2013) Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs27: 249–257.
65.
SoldatkinV (2013) A study of the efficacy and safety of valdoxan in the treatment of a depressive episode. Zh Nevrol Psikhiatr113: 36–42.
66.
StahlSM (2010) Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry71: 821–822.
67.
SteinDJAhokasAAde BodinatC (2008) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol28: 561–566.
68.
ThorpyM (2017) International classification of sleep disorders. Sleep Med Disord2017: 475–484.
69.
TordjmanSAndersonGMPichardN, et al. (2005) Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry57: 134–138.
70.
UradeCSMahakalkarSMTiplePG (2015) A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: a randomized, parallel-group, Phase IV study. J Pharmacol Pharmacother6: 198.
71.
van de WouwEEvenhuisHEchteldM (2012) Prevalence, associated factors and treatment of sleep problems in adults with intellectual disability: a systematic review. Res Dev Disabil33: 1310–1332.
72.
Van SomerenEJRiemersma-Van Der LekRF (2007) Live to the rhythm, slave to the rhythm. Sleep Med Rev11: 465–484.
73.
Van SomerenEJSwaabDFColendaCC, et al. (1999) Bright light therapy: improved sensitivity to its effects on rest–activity rhythms in Alzheimer patients by application of nonparametric methods. Chronobiol Int16: 505–518.
74.
VgontzasANFernandez-MendozaJLiaoD, et al. (2013) Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev17: 241–254.
75.
WasdellMBJanJEBombenMM, et al. (2008) A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res44: 57–64.
76.
WatsonNFBadrMSBelenkyG, et al. (2015) Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep38: 843–844.
77.
WilliamsWPIIIMcLinDEIIIDressmanMA, et al. (2016) Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep–wake disorders. Pharmacotherapy36: 1028–1041.
78.
WirojananJJacquemontSDiazR, et al. (2009) The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med5: 145–150.
79.
WrightBSimsDSmartS, et al. (2011) Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord41: 175–184.
80.
ZisapelN (2018) New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol175: 3190–3199.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
